Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

AIMS: Dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death among patients with heart failure with mildly reduced or preserved ejection fraction. In this study, the safety and efficacy of dapagliflozin according to background diuretic therapy and the influence of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chatur, Safia, Vaduganathan, Muthiah, Claggett, Brian, Vardeny, Orly, Desai, Akshay S, Jhund, Pardeep S, de Boer, Rudolf A, Lam, Carolyn S P, Kosiborod, Mikhail N, Shah, Sanjiv J, Martinez, Felipe, Inzucchi, Silvio E, Hernandez, Adrian F, Haddad, Tariq, Mitter, Sumeet S, Miao, Zi Michael, Petersson, Magnus, Maria Langkilde, Anna, McMurray, John J V, Solomon, Scott D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Fast Track Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484057/
https://www.ncbi.nlm.nih.gov/pubmed/37220093
http://dx.doi.org/10.1093/eurheartj/ehad283

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10484057/
https://www.ncbi.nlm.nih.gov/pubmed/37220093
http://dx.doi.org/10.1093/eurheartj/ehad283

Ejemplares similares